Bioanalytical method validation considerations for LC–MS/MS assays of therapeutic proteins. (June 2015)

• Record Type: Journal Article
• Authors: Duggan, Jeffrey X; Vazvaei, Faye; Jenkins, Rand
• Is Part Of: Bioanalysis. Volume 7:Number 11(2015)
• Page Start: 1389
• Page End: 1395
• Publication Date: 2015-06
• Subjects: Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio.15.69
• Languages: English
• ISSNs: 1757-6180

Abstract

This paper highlights the recommendations of a group of industry scientists in validating regulated bioanalytical LC–MS/MS methods for protein therapeutics in a 2015 AAPSJ White Paper. This group recommends that most of the same precision and accuracy validation criteria used for ligand-binding assays (LBAs) be applied to LC–MS/MS-based assays where proteins are quantified using the LC–MS/MS signal from a surrogate peptide after proteolytic digestion (PrD-LCMS methods). PrD-LCMS methods are generally more complex than small molecule LC–MS/MS assays and may often include LBA procedures, leading to the recommendation for a combination of chromatographic and LBA validation strategies and appropriate acceptance criteria. Several key aspects of this bioanalytical approach that are discussed in the White Paper are treated here in additional detail. These topics include selectivity/specificity, matrix effect, digestion efficiency, stability and critical reagent considerations.